Te Ahumairangi Investment Management Ltd
Position in LLY — ELI LILLY & Co
CIK 1832237
WELLINGTON, Q2
Position in LLY
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$3,022,563
+$506,993 QoQ
Shares Held
2,520
-7.9% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.49%
of 13F equity value
Holder Rank
#2,122
of 4,605 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Te Ahumairangi Investment Management Ltd holds $45,755,777 across 8 Drug Manufacturers - General names. LLY ranks #8 (6.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
31,084 | $7,894,403 | |
| 2 | AZN |
Astrazeneca PLC
|
34,479 | $6,537,907 | |
| 3 | MRK |
Merck & Co., Inc.
|
50,511 | $6,490,663 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
48,936 | $6,182,574 | |
| 5 | PFE |
Pfizer Inc
|
237,946 | $5,729,739 | |
| 6 | ABBV |
AbbVie Inc.
|
21,083 | $5,305,326 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
79,705 | $4,592,602 | |
| 8 | LLY |
ELI LILLY & Co
This page
|
2,520 | $3,022,563 |
All Filings in LLY
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,022,563 | 2,520 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $2,515,570 | 2,735 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,794,168 | 2,600 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $2,380,560 | 3,120 | Shares | Sole | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||